Literature DB >> 21424308

[Anesthesia and Angelman syndrome].

W Witte1, C Nobel, J Hilpert.   

Abstract

Angelman syndrome (AS) is a rare neurodevelopmental disorder with an incidence of 1:10,000-1:40,000 caused by deficient genetic imprinting in the chromosomal segment 15q11-q13. Experimental data suggest that the gamma-aminobutyric acid A (GABA(A)) receptor as well as the N-methyl-D-aspartate (NMDA) or α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptors may be affected by this condition. The first description of the syndrome goes back to 1965 when the British pediatrician Harry Angelman (1915-1996) recognized similar clinical features in three children. Angelman's description of puppet children was changed to happy puppet syndrome 2 years later before this euphemistic denotation was replaced by the concept Angelman syndrome over the years. Angelman syndrome is characterized by ataxia, jerky movements especially hand flapping, a seizure disorder with a characteristic electroencephalogram (EEG), severe learning difficulties, a happy disposition, lack of verbal communication and dysmorphic facial features. Most hospitalizations are caused by epilepsy and the most common indications for surgical procedures are in dental medicine. The first anesthesiology case report to be published dates back to 2001. A total of 13 cases have now been published and in 11 cases the age was registered (mean age 11.6 years, standard deviation 11.7 and 2 outliers aged 27 and 40 years). In this paper, the published case reports are contrasted with 15 cases of anesthesia in 6 patients with AS who underwent surgery during 14 years of routine operations at a Berlin anesthesiology clinic (mean age 15.9 years, standard deviation 4.2 with no outliers). Besides neurosurgical and orthopedic operations most were dental interventions. Summarized, these cases of anesthesia and the results of the published case reports allow the formulation of guidelines for administration of anesthesia in AS cases but do not permit conclusions on which method of anesthesia is the safest for AS patients. For the preoperative consultation and anesthetization, communication with the patients requires the aid of parents or other relatives. Water and reflecting surfaces may be used to gain contact with AS patients. Patients with AS feel pain like any other person although they are frequently smiling and laughing and this has to be considered especially in major surgery (e.g. scoliosis surgery). The most important life-threatening complication is bradycardia due to vagal hypertonia which can lead to asystole with delayed response to atropine. None of the Berlin patients had severe bradycardia but the complication has to be taken into consideration. The use of drugs to ensure complete reversal of neuromuscular relaxation should be avoided because anticholinergic agents could cause bradycardia. The use of sugammadex in cases of AS has not been tested. To avoid elevation of the vagal tone, the indications for laparascopy have to be considered very carefully. There is no evidence that any drug or hypnotic may be more appropriate or advantageous. Balanced anesthesia and total intravenous anesthesia are possible but the duration of drug effect has to be taken into account. If ketamine is used the side-effects of the drug (psychomimetic reactions, muscular rigidity) should be prevented by the consistent administration of propofol, midazolam or thiopental. Usually AS patients are agitated so that regional anesthesia techniques are difficult to administer. If regional anesthesia does have considerable advantages over general anesthesia in a particular case, peripheral regional anesthesia should be preferred, especially because scoliosis is often present. There is no evidence that AS patients cause more intubation problems but because of facial dysmorphia accurate evaluation is needed in advance. This is even more important for older AS patients because the dysmorphia tends to accelerate during the course of life. Although epilepsy is the primary feature of AS, not every EEG alteration indicates the presence of epilepsy. The advantage in using neuromonitoring for measuring the depth of anesthesia is limited. Administration of anticonvulsants must be continued if they were used preoperatively.

Entities:  

Mesh:

Year:  2011        PMID: 21424308     DOI: 10.1007/s00101-011-1873-4

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  42 in total

1.  Angelman syndrome.

Authors:  J Clayton-Smith; M E Pembrey
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

Review 2.  Angelman syndrome (AS, MIM 105830).

Authors:  Griet Van Buggenhout; Jean-Pierre Fryns
Journal:  Eur J Hum Genet       Date:  2009-05-20       Impact factor: 4.246

3.  Angelman syndrome: clinical findings and follow-up data of 14 patients.

Authors:  Bülent Kara; Birsen Karaman; Meral Ozmen; Rasim Ozgür Rosti; Mine Calişkan; Hülya Kayserili; Seher Başaran
Journal:  Turk J Pediatr       Date:  2008 Mar-Apr       Impact factor: 0.552

4.  Anaesthesia for Angelman syndrome.

Authors:  K R Ramanathan; D Muthuswamy; B J Jenkins
Journal:  Anaesthesia       Date:  2008-06       Impact factor: 6.955

5.  Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome.

Authors:  Edwin J Weeber; Yong-Hui Jiang; Ype Elgersma; Andrew W Varga; Yarimar Carrasquillo; Sarah E Brown; Jill M Christian; Banefsheh Mirnikjoo; Alcino Silva; Arthur L Beaudet; J David Sweatt
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

Review 6.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

7.  Angelman syndrome: are the estimates too low?

Authors:  R H Buckley; N Dinno; P Weber
Journal:  Am J Med Genet       Date:  1998-12-04

8.  Anaesthesia for an adult with Angelman syndrome.

Authors:  M Maguire
Journal:  Anaesthesia       Date:  2009-11       Impact factor: 6.955

9.  [Anesthesia in a patient with Angelman syndrome].

Authors:  C L Errando; M Murcia; A Gimeno; R Herrera
Journal:  Rev Esp Anestesiol Reanim       Date:  2007-11

10.  Behavior and neuropsychiatric manifestations in Angelman syndrome.

Authors:  Karine Pelc; Guy Cheron; Bernard Dan
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

View more
  3 in total

1.  Angelman syndrome and anaesthetic considerations.

Authors:  Jyotsna Agarwal; Rashmi Datta; C N Jaideep; Amit Sharma
Journal:  Indian J Anaesth       Date:  2017-01

Review 2.  A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome.

Authors:  Jessica Duis; Mark Nespeca; Jane Summers; Lynne Bird; Karen G C B Bindels-de Heus; M J Valstar; Marie-Claire Y de Wit; C Navis; Maartje Ten Hooven-Radstaake; Bianca M van Iperen-Kolk; Susan Ernst; Melina Dendrinos; Terry Katz; Gloria Diaz-Medina; Akshat Katyayan; Srishti Nangia; Ronald Thibert; Daniel Glaze; Christopher Keary; Karine Pelc; Nicole Simon; Anjali Sadhwani; Helen Heussler; Anne Wheeler; Caroline Woeber; Margaret DeRamus; Amy Thomas; Emily Kertcher; Lauren DeValk; Kristen Kalemeris; Kara Arps; Carol Baym; Nicole Harris; John P Gorham; Brenda L Bohnsack; Reid C Chambers; Sarah Harris; Henry G Chambers; Katherine Okoniewski; Elizabeth R Jalazo; Allyson Berent; Carlos A Bacino; Charles Williams; Anne Anderson
Journal:  Mol Genet Genomic Med       Date:  2022-02-11       Impact factor: 2.183

3.  Anesthetic Considerations for Angelman Syndrome: Case Series and Review of the Literature.

Authors:  Mary Ellen Warner; David P Martin; Mark A Warner; Ralitza H Gavrilova; Juraj Sprung; Toby N Weingarten
Journal:  Anesth Pain Med       Date:  2017-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.